|Videos|May 31, 2019

Dr Wayne Burton Discusses Key Takeaways From Migraine Peer Exchange

Wayne Burton, MD, former global corporate medical director for American Express, discusses what he views as the key takeaways from a migraine peer exchange he recently participated in.

Transcript:

You recently participated in a peer exchange discussion on migraine. What were some key takeaways from that conversation?

There were a number of highlights and takeaways from the peer exchange. We realized that migraine now affects more than 40 million Americans; many of them, [a] large number— perhaps over 40%– are not diagnosed or are misdiagnosed and there’s lots of opportunities now with new treatments especially for episodic and chronic patients with migraine.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Dr Wayne Burton Discusses Key Takeaways From Migraine Peer Exchange

Related Content

Specialty Pharmacy Drives Advanced Therapy Access: Fran Gregory, PharmD

Teclistamab Outperforms Len/Dex in High-Risk Smoldering Myeloma With Higher CR Rate, PFS: Omar Nadeem, MD

SENTRY Trial Shows Survival, Spleen Benefits in Myelofibrosis: Claire Harrison, MD

Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD

Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD

Trending on AJMC

EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology

MRD-Guided CLL Treatment Duration: Personalization or Malpractice?

Teclistamab Outperforms Len/Dex in High-Risk Smoldering Myeloma With Higher CR Rate, PFS: Omar Nadeem, MD

SENTRY Trial Shows Survival, Spleen Benefits in Myelofibrosis: Claire Harrison, MD

Paul Richardson, MD, Calls Mezigdomide “CAR T in a Pill” for Patients With R/R Multiple Myeloma